Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Last trade$5.30
Day change+$0.295 (+5.90%)
Day range$4.98 – $5.43
Volume177,239
Market cap$196M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$195.75M
Price / earnings
—
Price / book
0.99×
Price / sales
49.22×
EV / sales
21×
EV / EBITDA
-0.5×
Profitability
Earnings per share
-$4.12
Return on assets
-60.47%
Return on equity
-81.37%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.85×
Quick ratio
7.85×
Cash ratio
4.34×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$136.33M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TRDA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$905K
$898K
$875K
$1.3M
$1.61M
$1.95M
$20.56M
$37.4M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$905K
$898K
$875K
$1.3M
$1.61M
$1.95M
$20.56M
$37.4M
Selling, general and administrative
$10.23M
$10.49M
$10.12M
$9.55M
$10.3M
$10.92M
$10.27M
$9.86M
Research and development
$32.37M
$35.37M
$33.05M
$33.96M
$38.36M
$37.88M
$32.07M
$33.41M
Total operating expenses
$42.59M
$45.86M
$43.18M
$43.51M
$48.67M
$48.8M
$42.35M
$43.27M
Operating income
-$41.69M
-$44.96M
-$42.3M
-$42.21M
-$47.05M
-$46.85M
-$21.79M
-$5.87M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$39.72M
-$42.73M
-$39.68M
-$39.07M
-$43.48M
-$42.93M
-$17.35M
-$739K
Income taxes
$27K
$35K
$38K
$92K
$654K
$178K
$0
-$1.87M
Net income
-$39.74M
-$42.76M
-$39.72M
-$39.16M
-$44.13M
-$43.1M
-$17.35M
$1.13M
Net income attributable to common shareholders
-$39.74M
-$42.76M
-$39.72M
-$39.16M
-$44.13M
-$43.1M
-$17.35M
$1.13M
EBITDA
-$41.02M
-$44.12M
-$41.5M
-$41.32M
-$45.82M
-$45.82M
-$20.84M
-$4.88M
Basic earnings per share
-$0.94
-$1.01
-$0.95
-$0.94
-$1.06
-$1.04
-$0.42
$0.03
Diluted earnings per share
-$0.94
-$1.01
-$0.95
-$0.94
-$1.06
-$1.04
-$0.42
$0.03
Recent news
Company coverage with links to the original publishers.
Entrada Therapeutics announced positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 for DMD patients amenable to exon 45 skipping. The trial met primary safety and tolerability objectives at the 5 mg/kg dose with favorable safety profile and demonstrated a 0.10% mean increase in dystrophin production. The company expects significant increases in dystrophin production at higher doses in future cohorts and plans to report Cohort 2 data (10 mg/kg) in the first half of 2027.
Entrada Therapeutics announced that an independent Data Monitoring Committee has recommended advancing to Cohort 3 at the top dose of 18 mg/kg in the ELEVATE-44-201 Phase 1/2 clinical study of ENTR-601-44 for Duchenne muscular dystrophy. The dose escalation marks progress in understanding the drug's safety and efficacy profile. Cohort 1 data is expected by year-end 2026, with Cohort 2 data anticipated in Q1 2027.
Entrada Therapeutics granted 61,365 RSUs and options to purchase 19,425 shares to eight newly-hired non-executive employees under its 2025 Inducement Equity Plan, effective September 1, 2026. The options have an exercise price of $7.07 per share, with vesting schedules spanning four years for options and multiple years for RSUs, contingent on continued employment.
Entrada Therapeutics announced that an independent Data Monitoring Committee has recommended advancing to Cohort 2 of its ELEVATE-45-201 Phase 1/2 study at an increased dose of 10 mg/kg (up from 5 mg/kg in Cohort 1). The study evaluates ENTR-601-45 for treating Duchenne muscular dystrophy in exon 45 skipping amenable patients. The company remains on track to report Cohort 1 safety and pharmacokinetic data in mid-2026.
DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.